Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression

Paclitaxel is a first-line drug for treating epithelial ovarian cancer (EOC). However, prognosis for patients with advanced stage cancer remains poor due to primary or acquired drug resistance. Therefore, overcoming chemoresistance is one of the greatest challenges in treating EOC. In this study, we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Nakamura, Koji, Sawada, Kenjiro, Miyamoto, Mayuko, Kinose, Yasuto, Yoshimura, Akihiko, Ishida, Kyoso, Kobayashi, Masaki, Shimizu, Aasa, Nakatsuka, Erika, Hashimoto, Kae, Mabuchi, Seiji, Kimura, Tadashi
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2019
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363016/
https://ncbi.nlm.nih.gov/pubmed/30774764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26586
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados